Inclusion Criteria:  Adult patients Advanced NSCLC with PD-L1 TPS of 50% or greater Administration of first line pembrolizumab between January 2017 & December 2019  Exclusion Criteria:  Auto-immune disease Prior exposure to immunotherapy First dose pembrolizumab administered after December 2019